CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences Vienna Austria

Center of Molecular Biology and Gene Therapy Department of Internal Medicine Hematology and Oncology University Hospital Brno and Medical Faculty Masaryk University Brno Czech Republic

e Duve Institute Université catholique de Louvain Brussels Belgium

INSERM UMR1009 Institut Gustave Roussy Villejuif France

Ludwig Institute for Cancer Research Brussels Belgium

Université Paris Saclay UMR1009 Institut Gustave Roussy Villejuif France

Zobrazit více v PubMed

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC: Lyon, 2008.

Cazzola M, Kralovics R. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood 2014; 123: 3714–3719. PubMed

Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061. PubMed

James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144–1148. PubMed

Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779–1790. PubMed

Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–397. PubMed

Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3: e270. PubMed PMC

Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356: 459–468. PubMed PMC

Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369: 2379–2390. PubMed

Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369: 2391–2405. PubMed PMC

Michalak M, Groenendyk J, Szabo E, Gold LI, Opas M. Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. Biochem J 2009; 417: 651–666. PubMed

Molinari M, Eriksson KK, Calanca V, Galli C, Cresswell P, Michalak M et al. Contrasting functions of calreticulin and calnexin in glycoprotein folding and ER quality control. Mol Cell 2004; 13: 125–135. PubMed

Marty C, Pecquet C, Nivarthi H, Elkhoury M, Chachoua I, Tulliez M et al. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. Blood 2015; published ahead of print 25 November 2015 doi:10.1182/blood-2015-11-679571. PubMed

Chachoua IPC, El-Khoury M, Nivarthi H, Albu RI, Marty C, Gryshkova V et al. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood 2015; published ahead of print 14 December 2015 doi:10.1182/blood-2015-11-681932. PubMed

Passamonti F, Caramazza D, Maffioli M. JAK inhibitor in CALR-mutant myelofibrosis. N Engl J Med 2014; 370: 1168–1169. PubMed

Calreticulin and cancer